In vitro activities of DC-159a, a novel fluoroquinolone, against mycobacterium species

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2684-2686

  Disratthakit, Areeya ^a   Doi, Norio ^a  

^a RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DC 159A; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM KANSASII; NONHUMAN; PRIORITY JOURNAL;

AMINOPYRIDINES; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIA, ATYPICAL; MYCOBACTERIUM; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM CHELONAE; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; QUINOLINES; RIFAMPIN; SPECIES SPECIFICITY;

EID: 77952612052     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01545-09     Document Type: Article

References (15)

1. Brown-Elliott, B. A., R. J. Wallace, Jr., C. J. Crist, L. Mann, and R. W. Wilson. 2002. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob. Agents Chemother. 46:3283-3285.
2. Clark, C., K. Smith, L. Ednie, T. Bogdanovich, B. Dewasse, P. McGhee, and P. C. Appelbaum. 2008. In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 52:77-84.
3. Cynamon, M., M. R. Sklaney, and C. Shoen. 2007. Gatifloxacin in combination with rifampicin in a murine tuberculosis model. J. Antimicrob. Chemother. 60:429-432.
4. Drlica, K., X. Zhao, and B. Kreiswirth. 2008. Minimising moxifloxacin resistance with tuberculosis. Lancet Infect. Dis. 8:273-275.
5. Gillespie, S. H., and O. Billington. 1999. Activity of moxifloxacin against mycobacteria. J. Antimicrob. Chemother. 44:393-395.
6. Guillemin, I., V. Jarlier, and E. Cambau. 1998. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob. Agents Chemother. 42:2084-2088.
7. Hoshino, K., K. Inoue, Y. Murakami, Y. Kurosaka, K. Numba, Y. Kashimoto, S. Uoyama, R. Okumura, S. Higuchi, and T. Otani. 2008. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob. Agents Chemother. 52:65-76.
8. Jacobs, M. R. 2004. Fluoroquinolones as chemotherapeutics against mycobacterial infections. Curr. Pharm. Des. 10:3213-3220.
9. Komoriya, S., H. Inagaki, Y. Sugimoto, M. Nagamochi, R. Miyauchi, J. Kuroyanagi, T. Kitamura, K. Hoshino, Y. Murakami, M. Tachibana, Y. Imamura, H. Takahashi, and M. Takemura. 2006. DC-159a, a new generation of respiratory quinolone: synthesis, design, and biological evaluations, abstr. F1-0477. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., American Society for Microbiology, Washington, DC.
10. NCCLS. 2003. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; approved standard M24-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
11. Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, R. J. O'Brien, A. N. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med. 169:421-426.
12. Onodera, Y., T. Hirata, K. Hoshino, and T. Otani. 2007. DC-159a, a novel quinolone, showed high inhibitory activity against altered topoisomerases of Streptococcus pneumoniae and Mycobacterium tuberculosis, abstr. F1-2126. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., American Society for Microbiology, Washington, DC.
13. Rustomjee, R., C. Lienhardt, T. Kanyok, G. R. Davies, J. Levin, T. Mthiyane, C. Reddy, A. W. Strum, F. A. Sirgel, J. Allen, D. J. Coleman, B. Fourie, D. A. Mitchison, and the Gatifoxacin for TB (OFLOTUB) Study Team. 2008. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12:128-138.
14. van den Boogaard, J., G. S. Kibiki, E. R. Kisanga, M. J. Boeree, and R. E. Aarnoutse. 2009. New drug against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob. Agents Chemother. 53:849-862.
15. World Health Organization. 2008. Guideline for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland.